Subclinical carotid atherosclerosis in inflammatory bowel disease: a population-based cross-sectional study Authors: Alexander Akhgar, Bernhard Wernly, Alexandra Feldman, Johannes Bauer, Julian Eberhardt, Christian Jung, Bernhard Paulweber, Bernhard Iglseder, Eugen Trinka, Elmar Aigner, Stephan Zandanell Published: 2026 ABSTRACT AbstractObjectivePatients with inflammatory bowel disease (IBD) have an increased risk of cardiovascular and cerebrovascular events, but the underlying mechanisms remain unclear. We aimed to assess subclinical carotid atherosclerosis in IBD in a large population-based cohort.MethodsWe performed a cross-sectional analysis of the Paracelsus 10 000 cohort in Salzburg, Austria. Adults aged 40–77 years underwent standardised clinical evaluation, laboratory testing and bilateral carotid ultrasonography. The primary endpoint was carotid plaque burden; secondary endpoints included plaque presence, intima–media thickness, carotid stenosis, coronary artery calcium and polygenic risk scores. Multivariable ordered logistic regression models were adjusted for age, sex and comprehensive cardiovascular risk measures including Systematic Coronary Risk Evaluation 2 and Life’s Essential 8.ResultsAmong 9723 participants, 70 had IBD and 9653 served as controls. Patients with IBD had higher levels of high-sensitivity C reactive protein (median 0.15 vs 0.12 mg/dL; p=0.039) and lower ferritin levels (86 vs 117 ng/mL; p=0.018). Carotid plaque prevalence (40% vs 38%; p=0.79) and plaque burden distribution (p=0.82) were similar between groups. Intima–media thickness, carotid stenosis, coronary artery calcium score categories and polygenic risk scores were also comparable. In multivariable analysis, IBD was not associated with higher plaque burden (adjusted OR 1.49; 95% CI 0.88 to 2.55; p=0.139).ConclusionsIn this population-based cohort, IBD was not associated with increased subclinical carotid atherosclerosis. These findings suggest that cardiovascular risk in IBD may not be fully explained by atherosclerotic burden alone and may involve inflammation-related and prothrombotic mechanisms beyond atherosclerosis.Keywords: INFLAMMATORY BOWEL DISEASE, ULTRASONOGRAPHY, CARDIOVASCULAR COMPLICATIONS, INFLAMMATION WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS In this large population-based cohort with standardised vascular imaging, IBD was not associated with increased subclinical carotid atherosclerosis, coronary artery calcium or genetic cardiovascular risk. In this large population-based cohort with standardised vascular imaging, IBD was not associated with increased subclinical carotid atherosclerosis, coronary artery calcium or genetic cardiovascular risk. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings suggest that cardiovascular risk in IBD may not be fully explained by atherosclerotic burden alone and highlight the need to consider inflammation-driven and thrombotic mechanisms in risk assessment and prevention strategies. These findings suggest that cardiovascular risk in IBD may not be fully explained by atherosclerotic burden alone and highlight the need to consider inflammation-driven and thrombotic mechanisms in risk assessment and prevention strategies. Introduction Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic immune-mediated disorder characterised by relapsing transmural or mucosal inflammation of the gastrointestinal tract.1 With a prevalence of approximately 0.3% in Europe, IBD predominantly affects young adults and imposes a lifelong systemic inflammatory burden.2 Beyond intestinal manifestations, this chronic immune activation may promote vascular injury through endothelial dysfunction, oxidative stress, platelet hyperactivation and dysregulated lipid metabolism.3 4 Epidemiologic studies consistently demonstrate that patients with IBD face a modest but significant excess risk of major adverse cardiovascular and cerebrovascular events, with HRs of 1.15 to 1.36 compared with population controls, even after adjustment for traditional risk factors.5 This risk is most pronounced during periods of active disease and in younger patients, and has been formally acknowledged in the 2024 European Crohn’s and Colitis Organisation guidelines on extraintestinal manifestations.6 Yet the mechanisms underlying this excess risk remain poorly understood. Atherosclerosis—a chronic inflammatory process driven by innate and adaptive immune responses—represents a plausible mediator.7–9 However, whether the excess cardiovascular burden in IBD reflects accelerated structural plaque formation or is driven predominantly by inflammation-mediated, non-atherosclerotic pathways such as thromboembolism and endothelial dysfunction remains uncertain and has direct implications for prevention and risk stratification.10 Existing imaging data are limited and inconsistent. Meta-analyses of subclinical atherosclerosis in IBD report only modest and heterogeneous differences in carotid intima–media thickness (IMT) and arterial stiffness compared with controls.11 In a Danish cohort, patients with IBD showed higher coronary calcium scores but not a greater prevalence of obstructive coronary disease, suggesting that subclinical structural changes may not fully explain the observed event excess.12 These discrepant findings highlight the need for large, population-based studies with standardised vascular imaging to clarify the relationship between IBD and subclinical atherosclerosis. Carotid ultrasonography provides a validated, non-invasive tool for the assessment of subclinical atherosclerosis at the population level, enabling quantification of plaque presence, plaque burden, IMT and stenosis severity.13 The Paracelsus 10 000 (P10) study—a population-based cohort of nearly 10 000 adults in Salzburg, Austria—offers a unique setting for this investigation, combining standardised bilateral carotid ultrasonography with comprehensive cardiovascular risk profiling, genome-wide genotyping enabling polygenic risk score analysis and coronary artery calcium scoring in a large subset.14 We therefore assessed the association between IBD and subclinical carotid atherosclerosis in the P10 cohort, complemented by coronary calcium scoring and polygenic cardiovascular risk profiling in nested subsets, and hypothesised that IBD would not be independently associated with increased atherosclerotic burden after adjustment for cardiovascular risk factors—suggesting a potential contribution of non-atherosclerotic mechanisms in IBD-associated cardiovascular risk. Methods Study population We analysed participants recruited between 2013 and 2020 from the P10 cohort, a population-based study conducted in Salzburg, Austria, enrolling 10 044 adults aged 40 to 77 years through random sampling from the national registry. For the present analysis, we included participants with complete data on IBD status, carotid ultrasonography, age and sex. A participant flow chart illustrating inclusion and exclusion criteria is provided in figure 1. Of the 10 044 participants originally enrolled in the P10 cohort, 9723 participants were included in the final analysis. Of these, 70 had IBD—51 with ulcerative colitis and 19 with Crohn’s disease—and 9653 served as controls. This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies (online supplemental file 1). Flow diagram of study inclusion and nested analysis subsets. From the Paracelsus 10 000 cohort, 321 participants with missing data in variables required for the primary analysis were excluded. The final study population comprised 9723 participants, including 70 with inflammatory bowel disease and 9653 controls. Nested subsets with available coronary artery calcium scores and polygenic risk scores are shown. Clinical assessment All participants underwent standardised clinical evaluation, laboratory testing and structured interviews on medical history, lifestyle and medication use. Laboratory analyses included lipid profiles, glucose metabolism markers and high-sensitivity C reactive protein. Cardiovascular health was additionally quantified using the American Heart Association Life’s Essential 8 (LE8) score, a composite measure encompassing diet, physical activity, nicotine exposure, sleep, body mass index, blood pressure, lipid levels and glycaemic status, with higher scores reflecting more favourable cardiovascular health.15 IBD status was ascertained by physician-confirmed diagnosis based on medical records and structured patient interview, and classified as ulcerative colitis or Crohn’s disease. Carotid ultrasonography Bilateral carotid ultrasonography was performed by a single experienced sonographer using a standardised protocol. Carotid plaques were defined as focal structures protruding into the lumen with a thickness exceeding 1.5 mm and an area exceeding 2.9 mm². Total plaque area was calculated bilaterally and classified into four ordered categories: no plaque (0 mm²), minimal (1–10 mm²), moderate (11–50 mm²) and extensive (>50 mm²). Carotid stenosis was graded according to European Carotid Surgery Trial criteria.16 IMT was measured as a continuous marker of vascular ageing. Additional assessments In a nested subset of participants with available genotype data (n=1699; 1682 controls and 17 with IBD), polygenic risk scores for coronary artery disease (PGS003725) and stroke (PGS000039) were derived from genome-wide association study summary statistics and PGS Catalogue weights, standardised, and used for comparative analysis between groups.17–19 Coronary artery calcium scoring was available in a slightly smaller subset (n=1683; 1666 controls and 17 with IBD), performed by CT and quantified using the Agatston scoring method, a standardised CT-based measure of coronary artery calcification burden, categorised as 0, 1–100, 101–300 and >300.20 Endpoints The primary endpoint was carotid plaque burden, assessed as an ordered categorical variable with four levels. Secondary endpoints included carotid stenosis severity, maximum IMT, coronary artery calcium score category and polygenic risk scores for coronary artery disease and stroke. Statistical analysis Continuous variables are presented as medians with IQRs and compared using Wilcoxon rank-sum tests. Categorical variables are presented as numbers and percentages and compared using χ2 or Fisher’s exact tests. Ordered logistic regression was used to model the association between IBD and ordered categorical outcomes, with results expressed as ORs with 95% CIs. Four hierarchical models were fitted: an unadjusted model; a model adjusted for age and sex; a model adjusted for Systematic Coronary Risk Evaluation 2 (SCORE2), a validated European algorithm estimating the 10-year risk of fatal and non-fatal cardiovascular disease,21 and a model adjusted for age, sex and the LE8 total score. For the coronary calcium subset, an additional model incorporating the coronary artery disease polygenic risk score was fitted. Subgroup analyses examined ulcerative colitis and Crohn’s disease separately using the same model structure. All tests were two-sided, with a significance threshold of p<0.05. Analyses were performed using Stata, V.17 (StataCorp). Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Results Study population Of the 9723 participants included in this analysis, 70 had IBD, comprising 51 with ulcerative colitis and 19 with Crohn’s disease, and 9653 served as controls. The median age was 53 years (IQR, 49–61) in the IBD group and 55 years (IQR, 50–62) in the control group (p=0.19); 50% and 48% were male, respectively (p=0.78) (table 1). Table 1Baseline characteristics of study participantsCharacteristicControl (N=9653)IBD (N=70)P valueDemographics Age, year55 (50–62)53 (49–61)0.19 Male sex, n (%)4662 (48)35 (50)0.78Anthropometric measurements Height, cm171(164–177)168(165–178)0.97 Weight, kg76 (65–87)76 (67–82)0.58 BMI, kg/m²26 (23–29)26 (24–27)0.64 BMI ≥30 kg/m², n (%)1860 (19)8 (11)0.096 Waist circumference, cm93 (84–102)92 (87–98)0.91Laboratory values HbA1c, %5.4 (5.3–5.6)5.5 (5.3–5.7)0.51 Creatinine, mg/dL0.8 (0.7–1.0)0.8 (0.7–1.0)0.60 eGFR (CKD-EPI), mL/min/1.73 m²89 (79–98)91 (81–99)0.65 Total cholesterol, mg/dL209(184–234)200(178–224)0.11 LDL cholesterol, mg/dL140(116–165)130(110–154)0.072 HDL cholesterol, mg/dL61 (50–74)59 (51–72)0.57 Triglycerides, mg/dL97 (71–137)112 (74–145)0.34 Lipoprotein(a), nmol/L14 (5–45)17 (8–47)0.29 Ferritin, ng/mL117 (64–201)86 (45–164)0.018 High-sensitivity CRP, mg/dL0.12(0.06–0.24)0.15(0.08–0.31)0.039 Uric acid, mg/dL5 (4–6)5 (4–6)0.78Cardiometabolic factors Metabolic syndrome, n (%)2442 (26)16 (24)0.78 Elevated triglycerides ≥150 mg/dL, n (%)2504 (26)18 (27)0.89 Low HDL cholesterol, n (%)1021 (11)7 (11)0.98 Elevated blood pressure, n (%)5714 (59)42 (60)0.92 Elevated fasting glucose, n (%)2590 (27)22 (33)0.28Diabetes status No diabetes, n (%)6107 (63)40 (57) Pre-diabetes, n (%)3026 (31)25 (36) Diabetes, n (%)520 (5)5 (7)0.54 Treatment for type 2 diabetes, n (%)304 (3)3 (4)0.59Pre-existing conditions Known hypertension, n (%)2189 (23)17 (24)0.75 Known coronary artery disease, n (%)204 (2)1 (1)0.69 Known atrial fibrillation, n (%)155 (2)6 (9)<0.001 Previous stroke, n (%)205 (2)4 (6)<0.001 Chronic kidney disease, n (%)641 (7)4 (6)0.87Medications Statin therapy, n (%)790 (8)5 (7)0.75 Antihypertensive therapy, n (%)1993 (21)14 (20)0.89 Use of glucocorticoids, n (%)46 (<1)4 (6)<0.001Lifestyle factors Smoking status0.53 Never smoker4100 (45)33 (51) Previous smoker3338 (37)23 (35) Current smoker1683 (18)9 (14)Values are presented as median (IQR) for continuous variables and number (percentage) for categorical variables. Continuous variables were compared using the Mann-Whitney U test and categorical variables using the χ² test or Fisher’s exact test, as appropriate. BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin A1c; HDL, High-Density Lipoprotein; IBD, inflammatory bowel disease; LDL, Low-Density Lipoprotein. Baseline characteristics of study participants Values are presented as median (IQR) for continuous variables and number (percentage) for categorical variables. Continuous variables were compared using the Mann-Whitney U test and categorical variables using the χ² test or Fisher’s exact test, as appropriate. BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin A1c; HDL, High-Density Lipoprotein; IBD, inflammatory bowel disease; LDL, Low-Density Lipoprotein. Baseline characteristics Baseline characteristics were largely comparable between groups, except for higher levels of high-sensitivity C reactive protein (median, 0.15 vs 0.12 mg/dL; p=0.039) and lower ferritin levels (86 vs 117 ng/mL; p=0.018) in the IBD group. A higher prevalence of previous stroke (6% vs 2%, p<0.001), atrial fibrillation (9% vs 2%, p<0.001) and glucocorticoid use (6% vs <1%, p<0.001) was observed among patients with IBD. Lipid profiles, body mass index, cardiovascular risk scores (SCORE2), statin therapy and antihypertensive treatment were otherwise similar between groups (table 1). Primary endpoint: carotid plaque burden The distribution of carotid plaque burden categories was similar between patients with IBD and controls (p=0.82). Among patients with IBD, 60% had no plaque, 10% minimal plaque, 24% moderate plaque and 6% extensive plaque; the corresponding proportions in controls were 62%, 12%, 20% and 6% (table 2, figure 2). In unadjusted ordered logistic regression, IBD was not associated with higher plaque burden (OR, 1.10; 95% CI 0.69 to 1.75; p=0.691). After adjustment for age and sex, the OR was 1.27 (95% CI 0.77 to 2.11; p=0.347), and after adjustment for SCORE2, it was 1.56 (95% CI 0.94 to 2.60; p=0.088). In the fully adjusted model incorporating age, sex and LE8 total score, the OR was 1.49 (95% CI 0.88 to 2.55; p=0.139). Results were consistent across all models (table 3). Table 2Cardiovascular outcomesOutcomeControlIBDP valuePrimary outcome (full cohort) N=9653 N=70 Carotid plaque burden categories—no. (%) 0.82 No plaque (0 mm²)5943 (62)42 (60) Minimal plaque (1–10 mm²)1190 (12)7 (10) Moderate plaque (11–50 mm²)1952 (20)17 (24) Extensive plaque (>50 mm²)568 (6)4 (6) Secondary outcomes (full cohort) Presence of carotid plaque—no. (%)3710 (38)28 (40)0.79IMT Maximum IMT0.67(0.58–0.76)0.67(0.58–0.75)0.69 IMT >0.9 mm–no. (%)709 (7)4 (6)0.60Carotid stenosis categories—no. (%)0.98 No stenosis7147 (74)52 (74) ECST <50%2443 (25)18 (26) ECST 50%–69%39 (<1%)0 (0) ECST 70%–80%8 (<1%)0 (0) ECST >80%4 (<1%)0 (0)Subset with coronary artery calcium scoreN=1666N=17 Agatston score categories—no. (%)0.50 0948 (57)10 (59) 1–100530 (32)7 (41) 101–30095 (6)0 (0) >30093 (6)0 (0)Subset with PGSsN=1682N=17CAD PGS CAD PGS (continuous)−0.80(−1.31 to −0.30)−0.63(−0.90 to −0.39)0.46 CAD PGS tertiles—no. (%)0.14 Low CAD PGS (T1)566 (34)3 (18) Intermediate CAD PGS (T2)558 (33)9 (53) High CAD PGS (T3)558 (33)5 (29)Stroke PGS Stroke PGS (continuous)−0.35(−0.50 to −0.20)−0.34(−0.48 to −0.17)0.75 Stroke PGS tertiles—no. (%)0.83 Low stroke PGS (T1)570 (34)6 (35) Intermediate stroke PGS (T2)555 (33)5 (29) High stroke PGS (T3)557 (33)6 (35)Values are presented as median (IQR) for continuous variables and number (percentage) for categorical variables. CAD, coronary artery disease; ECST, European Carotid Surgery Trial; IBD, inflammatory bowel disease; IMT, intima–media thickness; PGS, polygenic risk score. Cardiovascular outcomes Values are presented as median (IQR) for continuous variables and number (percentage) for categorical variables. CAD, coronary artery disease; ECST, European Carotid Surgery Trial; IBD, inflammatory bowel disease; IMT, intima–media thickness; PGS, polygenic risk score. Distribution of carotid plaque burden by IBD status. Stacked bars represent the proportion of participants across four plaque burden categories (no plaque, minimal (1–10 mm²), moderate (11–50 mm²) and extensive (>50 mm²)) in individuals with and without IBD. No significant difference was observed between groups (p=0.82). IBD, inflammatory bowel disease. Table 3Association between IBD and carotid plaque burden—ordered logistic regressionModel 1Model 2Model 3Model 4Unadjusted+ age, sex+ SCORE2+ age, sex, LE8IBD versus control—OR (95% CI)1.10 (0.69 to 1.75)1.27 (0.77 to 2.11)1.56 (0.94 to 2.60)1.49 (0.88 to 2.55)P value0.6910.3470.0880.139Ulcerative colitis versus control—OR (95% CI)1.29 (0.75 to 2.20)1.42 (0.80 to 2.52)1.58 (0.87 to 2.87)—P value0.3530.2280.129—Crohn’s disease versus control—OR (95% CI)0.70 (0.27 to 1.81)0.89 (0.30 to 2.59)1.49 (0.55 to 4.04)—P value0.4650.8250.429—Model 1 was unadjusted. Model 2 was adjusted for age and sex. Model 3 was adjusted for SCORE2. Model 4 was adjusted for age, sex, and LE8 total score. ORs with 95% CIs reflect the proportional odds of being in a higher carotid plaque burden category. Subtype analyses were not performed for model 4 due to limited sample size. IBD, inflammatory bowel disease; LE8, Life’s Essential 8; SCORE2, Systematic Coronary Risk Evaluation 2. Association between IBD and carotid plaque burden—ordered logistic regression Model 1 was unadjusted. Model 2 was adjusted for age and sex. Model 3 was adjusted for SCORE2. Model 4 was adjusted for age, sex, and LE8 total score. ORs with 95% CIs reflect the proportional odds of being in a higher carotid plaque burden category. Subtype analyses were not performed for model 4 due to limited sample size. IBD, inflammatory bowel disease; LE8, Life’s Essential 8; SCORE2, Systematic Coronary Risk Evaluation 2. Subgroup analyses: ulcerative colitis and Crohn’s disease In analyses stratified by IBD subtype, neither ulcerative colitis nor Crohn’s disease was significantly associated with carotid plaque burden. For ulcerative colitis, the unadjusted OR was 1.29 (95% CI 0.75 to 2.20; p=0.353), increasing to 1.42 (95% CI 0.80 to 2.52; p=0.228) after adjustment for age and sex, and to 1.58 (95% CI 0.87 to 2.87; p=0.129) after adjustment for SCORE2. For Crohn’s disease, the corresponding ORs were 0.70 (95% CI 0.27 to 1.81; p=0.465), 0.89 (95% CI 0.30 to 2.59; p=0.825), and 1.49 (95% CI 0.55 to 4.04; p=0.429), respectively. The divergent point estimates suggest potential phenotypic heterogeneity, although neither subgroup reached statistical significance (table 3). Secondary endpoints: IMT and carotid stenosis Maximum IMT was similar between patients with IBD and controls (median, 0.67 vs 0.67 mm; p=0.69). The prevalence of IMT >0.9 mm was also comparable (6% vs 7%; p=0.60). Carotid stenosis categories did not differ between groups (p=0.98) (table 2). Coronary artery calcium scoring In the subset of participants with available coronary calcium scoring (1683 participants: 17 IBD and 1666 controls), the distribution of Agatston score categories did not differ significantly between groups (p=0.50). Among patients with IBD, 59% had a score of 0% and 41% had a score of 1–100; no patients with IBD had a score above 100. The corresponding proportions in controls were 57%, 32%, 6% and 6% for increasing categories (table 2). In ordered logistic regression analysis of coronary artery calcium burden, IBD was not associated with higher calcium categories across all models, including after adjustment for the polygenic risk score (table 4). In contrast, the coronary artery disease polygenic risk score was strongly associated with calcium burden (OR 1.96; 95% CI 1.69 to 2.28; p<0.001). Table 4Association between IBD and coronary artery calcium score—ordered logistic regression (nested subset) (N=1699; 1682 controls and 17 participants with IBD)Model 1Model 2Model 3Model 4+ age, sex+ SCORE2+ SCORE2 + PGS+ age, sex, LE8IBD versus control—OR (95% CI)0.95 (0.35 to 2.61)0.95 (0.33 to 2.72)1.00 (0.35 to 2.91)1.02 (0.34 to 3.08)P value0.9200.9300.9950.974PGS003725 (per SD increase)—OR (95% CI)——1.96 (1.69 to 2.28)—P value——<0.001—Model 1 was adjusted for age and sex. Model 2 was adjusted for SCORE2. Model 3 was adjusted for SCORE2 and the coronary artery disease polygenic risk score (PGS003725). Model 4 was adjusted for age, sex and LE8 total score. ORs with 95% CIs reflect the proportional odds of being in a higher coronary artery calcium category (0, 1–100, 101–300 and >300). IBD, inflammatory bowel disease; LE8, Life’s Essential 8; PGS, polygenic risk score; SCORE2, Systematic Coronary Risk Evaluation 2. Association between IBD and coronary artery calcium score—ordered logistic regression (nested subset) (N=1699; 1682 controls and 17 participants with IBD) Model 1 was adjusted for age and sex. Model 2 was adjusted for SCORE2. Model 3 was adjusted for SCORE2 and the coronary artery disease polygenic risk score (PGS003725). Model 4 was adjusted for age, sex and LE8 total score. ORs with 95% CIs reflect the proportional odds of being in a higher coronary artery calcium category (0, 1–100, 101–300 and >300). IBD, inflammatory bowel disease; LE8, Life’s Essential 8; PGS, polygenic risk score; SCORE2, Systematic Coronary Risk Evaluation 2. Polygenic risk score analysis In the subset with available polygenic risk scores (1699 participants: 17 IBD and 1682 controls), the distribution of coronary artery disease and stroke polygenic risk score tertiles did not differ significantly between groups (p=0.14 and p=0.83, respectively). Continuous PGS values were also similar between patients with IBD and controls (table 2). Discussion In this population-based study of 9723 participants, we found no significant association between IBD and subclinical carotid atherosclerosis across four hierarchical models of increasing covariate adjustment. The distribution of carotid plaque burden, quantified as an ordered categorical outcome, did not differ between patients with IBD and controls, and results were consistent after adjustment for age and sex, composite cardiovascular risk, and the Life’s Essential 8 score. Our findings are broadly in line with previous studies demonstrating that patients with IBD have a modestly increased incidence of major cardiovascular and cerebrovascular events, whereas meta-analyses of subclinical atherosclerosis have shown only modest and inconsistent differences in carotid IMT and arterial stiffness.22–24 This apparent paradox suggests that cardiovascular risk in IBD may be mediated less by accelerated plaque accumulation than by other inflammation-driven mechanisms. Notably, the modest increase in point estimates across adjustment models—from an OR of 1.10 unadjusted to 1.56 after SCORE2 adjustment—reflects negative confounding, whereby patients with IBD in this population-based cohort had more favourable cardiovascular risk profiles than controls, partially masking any underlying association. Despite this, no model reached statistical significance, reinforcing the null finding. In our cohort, patients with IBD had a higher prevalence of previous stroke and atrial fibrillation despite similar atherosclerotic burden, suggesting that cardiovascular and cerebrovascular complications may arise through non-atherosclerotic pathways. These observations should be interpreted with caution given the small absolute number of events. However, mechanistic studies support this interpretation: IBD is associated with a prothrombotic state, platelet hyperactivation, and elevated procoagulant factors, conferring a threefold to fourfold increased risk of thromboembolism independent of plaque burden.25 26 Importantly, arterial events in IBD correlate more strongly with disease activity and inflammatory markers than with traditional risk factors, implicating systemic inflammation as a trigger of acute vascular events.5 26–28 The temporal pattern observed in Danish cohorts, with a peak in ischaemic heart disease risk during the first year after diagnosis and a persistently elevated but lower risk thereafter, further supports inflammation as a key driver of early cardiovascular complications.29 The polygenic risk score analysis provides additional mechanistic insight. In the nested subset undergoing coronary artery calcium scoring, the coronary artery disease polygenic risk score was strongly and independently associated with calcium burden (OR 1.96; 95% CI 1.69 to 2.28; p<0.001), confirming its validity as a genetic risk marker in this cohort. By contrast, IBD was unassociated with coronary calcium burden across all models, including after polygenic risk score adjustment (OR 1.00; 95% CI 0.35 to 2.91). These findings indicate that inherited cardiovascular susceptibility and IBD-associated cardiovascular risk represent orthogonal dimensions—the excess risk in IBD is unlikely to reflect genetic predisposition to atherosclerosis but rather acquired, inflammation-mediated and prothrombotic processes. Subgroup analyses revealed divergent point estimates for ulcerative colitis and Crohn’s disease, with ulcerative colitis showing a numerically higher OR for plaque burden across models compared with Crohn’s disease, where estimates were close to or below unity. Although neither subtype reached statistical significance, this pattern may reflect genuine heterogeneity in inflammatory profiles, disease distribution or treatment exposure between the two conditions. Larger, adequately powered studies with IBD subtype stratification are required to determine whether ulcerative colitis confers a distinct subclinical vascular phenotype. These findings have clinical implications. Conventional cardiovascular risk models such as SCORE2 may underestimate risk in IBD because they do not capture the contribution of systemic inflammation and thrombosis.30 Improved risk stratification incorporating markers of disease activity and inflammatory burden may be warranted. Therapeutically, the predominance of non-atherosclerotic mechanisms suggests that optimal inflammatory control may be more important than traditional lipid-lowering strategies alone in reducing cardiovascular events in IBD. Notably, glucocorticoid use, observed in a relevant proportion of patients with IBD in our cohort, may independently modulate cardiovascular risk and warrants careful clinical consideration.31 This study has several limitations. First, the number of participants with IBD was relatively small, which limited statistical power, particularly for subgroup analyses, and modest associations cannot be excluded. The prevalence of IBD in our cohort (0.72%) was within the expected range for European populations (approximately 0.4%–0.8%), supporting the general representativeness of the sample.32–34 However, participation bias cannot be excluded. In particular, individuals with more severe or active IBD may be under-represented, as these patients are typically already engaged in frequent specialist care and may be less inclined to participate in additional population-based health assessments. This potential underrepresentation of patients with higher inflammatory burden may have attenuated potential associations between IBD and subclinical atherosclerosis. Second, the cross-sectional design precludes assessment of temporal relationships between IBD, systemic inflammation, and the development or progression of atherosclerosis. Third, although IBD status was based on physician-confirmed diagnosis using structured interviews and available medical records, detailed disease-specific data were not available. In particular, information on disease duration, activity, extent, cumulative inflammatory burden, and treatment exposure (including biologic and small molecule therapies) was lacking. These factors are likely key determinants of cardiovascular risk in IBD and their absence limits mechanistic interpretation. Fourth, several observed clinical differences, including higher rates of atrial fibrillation and prior stroke in the IBD group, were based on small absolute event numbers and should therefore be interpreted with caution. In addition, medication-specific subgroup analyses (eg, stratified by statin or antihypertensive therapy) were not feasible due to the limited number of participants with IBD, resulting in small subgroup sizes and limited statistical power. Finally, the population-based recruitment strategy enhances generalisability to the general population but may limit applicability to higher-risk IBD populations typically managed in tertiary referral centres. Despite these limitations, the study benefits from a large, well-characterised population-based cohort, standardised vascular imaging, and the integration of coronary calcium and genetic risk data, providing a robust framework for the assessment of subclinical atherosclerosis in IBD. In conclusion, patients with IBD in this population-based cohort did not demonstrate increased subclinical carotid or coronary atherosclerosis despite elevated inflammatory markers and a known excess risk of cardiovascular events. These findings do not support a major association between IBD and structural atherosclerotic burden. However, given the limited sample size and lack of disease-specific data, modest associations cannot be excluded. The results are consistent with the hypothesis that inflammation-mediated and prothrombotic mechanisms may contribute substantially to cardiovascular risk in IBD. Prospective studies incorporating detailed disease phenotyping are required to further elucidate these relationships. Supplementary material Acknowledgements We thank all participants of the Paracelsus 10 000 study and the entire study team for their commitment and contribution to data collection and cohort maintenance. We further acknowledge the foundational work of the Paracelsus 10 000 investigators and express our gratitude to the late Professor Gunther Ladurner and Priv.-Doz. Dr Reinhold Fartacek, who initiated and conceptualised the study. Footnotes Funding: The study was financially supported by the Land Salzburg, the Salzburger Landeskliniken (SALK, the Health Care Provider of the University Hospitals Landeskrankenhaus and Christian Doppler Klinik), the Paracelsus Medical University Salzburg, the Austrian health insurance (Österreichische Gesundheitskasse-ÖGK) and by unrestricted grants from Bayer, AstraZeneca, Sanofi-Aventis, Boehringer-Ingelheim. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: The Paracelsus 10 000 study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the State of Salzburg, Austria (reference number: 415-E/1521/3-2012). All participants provided written informed consent prior to inclusion in the study. The present analysis was performed on pseudonymised data in accordance with applicable data protection regulations. Data availability free text: Not applicable. Data availability statement Data are available on reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available on reasonable request.